Segarra Marta, García-Martínez Ana, Sánchez Montse, Hernández-Rodríguez José, Lozano Ester, Grau Josep M, Cid Maria C
Vasculitis Research Unit, Department of Internal Medicine, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain.
Ann Rheum Dis. 2007 Nov;66(11):1429-35. doi: 10.1136/ard.2006.068148. Epub 2007 May 14.
Gelatinases (MMP2 and MMP9) are expressed in giant-cell arteritis (GCA) and are thought to play a role in vessel disruption. However, their activation status and enzymatic activity have not been evaluated. Our aim was to investigate the distribution and proteolytic activity of gelatinases in GCA lesions at different stages.
Expression of MMP2, MMP9, MMP2-activator MMP14 and their natural inhibitors TIMP1 and TIMP2 was determined by real-time PCR and immunohistochemistry in temporal artery sections from 46 patients and 12 controls. MMP activation status and enzymatic activity were assessed by gelatin and film in situ zymography.
Vascular smooth muscle cells from normal specimens constitutively expressed pro-MMP2 and its inhibitor TIMP2 with no resulting proteolytic activity. In GCA MMP2, MMP9 and MMP14 were strongly expressed in their active form by infiltrating leucocytes. Inflamed arteries also expressed TIMP1 and TIMP2. However, the MMP9/TIMP1 and MMP2/TIMP2 ratios were higher in patients compared with controls, indicating an increased proteolytic balance in GCA which was confirmed by in situ zymography. Maximal gelatinase expression and activity occurred at the granulomatous areas surrounding the internal elastic lamina (IEL). Myointimal cells also expressed MMPs and exhibited proteolytic activity, suggesting a role for gelatinases in vascular remodelling and repair.
GCA lesions show intense expression of gelatinases. Activators and inhibitors are regulated to yield enhanced gelatinase activation and proteolytic activity. Distribution of expression and proteolytic activity suggests that gelatinases have a major role not only in the progression of inflammatory infiltrates and vessel destruction but also in vessel repair.
明胶酶(基质金属蛋白酶2和基质金属蛋白酶9)在巨细胞动脉炎(GCA)中表达,被认为在血管破坏中起作用。然而,它们的激活状态和酶活性尚未得到评估。我们的目的是研究不同阶段GCA病变中明胶酶的分布和蛋白水解活性。
通过实时聚合酶链反应和免疫组织化学法,测定46例患者和12例对照者颞动脉切片中基质金属蛋白酶2、基质金属蛋白酶9、基质金属蛋白酶2激活剂基质金属蛋白酶14及其天然抑制剂金属蛋白酶组织抑制因子1和金属蛋白酶组织抑制因子2的表达。通过明胶和膜原位酶谱法评估基质金属蛋白酶的激活状态和酶活性。
正常标本的血管平滑肌细胞组成性表达前基质金属蛋白酶2及其抑制剂金属蛋白酶组织抑制因子2,无蛋白水解活性产生。在GCA中,基质金属蛋白酶2、基质金属蛋白酶9和基质金属蛋白酶14以活性形式在浸润的白细胞中强烈表达。炎症动脉也表达金属蛋白酶组织抑制因子1和金属蛋白酶组织抑制因子2。然而,与对照组相比,患者的基质金属蛋白酶9/金属蛋白酶组织抑制因子1和基质金属蛋白酶2/金属蛋白酶组织抑制因子2比值更高,表明GCA中的蛋白水解平衡增加,这通过原位酶谱法得到证实。最大明胶酶表达和活性出现在内弹性膜(IEL)周围的肉芽肿区域。肌内膜细胞也表达基质金属蛋白酶并表现出蛋白水解活性,提示明胶酶在血管重塑和修复中起作用。
GCA病变显示明胶酶强烈表达。激活剂和抑制剂受到调节,以增强明胶酶的激活和蛋白水解活性。表达和蛋白水解活性的分布表明,明胶酶不仅在炎症浸润和血管破坏的进展中起主要作用,而且在血管修复中也起主要作用。